Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All quercetin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchQuercetinQuercetin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Case 92% Improvement Relative Risk Quercetin  Arslan et al.  Prophylaxis  RCT Does quercetin + vitamin C and bromelain reduce COVID-19 infections? RCT 113 patients in Turkey (March - August 2020) Fewer cases with quercetin + vitamin C and bromelain (p=0.031) c19early.org Arslan et al., SSRN, November 2020 Favors quercetin Favors control

Synergistic Effect of Quercetin and Vitamin C Against COVID-19: Is a Possible Guard for Front Liners

Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Quercetin for COVID-19
24th treatment shown to reduce risk in July 2021
 
*, now known with p = 0.0031 from 11 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19early.org
Small prophylaxis RCT with 113 patients showing fewer cases with quercetin + vitamin C + bromelain prophylaxis. NCT04377789 (history). Note that this paper disappeared from SSRN without explanation.
This is the 1st of 10 COVID-19 RCTs for quercetin, which collectively show efficacy with p=0.0049.
This is the 1st of 11 COVID-19 controlled studies for quercetin, which collectively show efficacy with p=0.0031.
This study is excluded in the after exclusion results of meta analysis: paper no longer available at the source, and the contact does not reply to queries.
risk of case, 91.7% lower, RR 0.08, p = 0.03, treatment 1 of 71 (1.4%), control 9 of 42 (21.4%), NNT 5.0, adjusted per study, inverted to make RR<1 favor treatment.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Arslan et al., 16 Nov 2020, Randomized Controlled Trial, Turkey, preprint, 7 authors, study period 20 March, 2020 - 31 August, 2020, this trial uses multiple treatments in the treatment arm (combined with vitamin C and bromelain) - results of individual treatments may vary, trial NCT04377789 (history).
This PaperQuercetinAll
Abstract: 1 Synergistic Effect of Quercetin and Vitamin C Against COVID-19: Is A Possible Guard for Front liners? Bengu Arslan1, Nurcan Ucuncu Ergun1, Seyma Topuz1, Seda Yilmaz Semerci2, Nurettin Suner3, Ali Kocatas4, Hasan Onal1 1Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Department of Pediatric Nutrition and Metabolism Clinics, Istanbul, Turkey 2Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Department of Neonatology, Istanbul, Turkey 3Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Department of General Medicine, Istanbul, Turkey 4Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Departmento f General Surgery, Istanbul, Turkey Bengu Arslan, Postdoctorate Fellow of Pediatric Nutrition and Metabolism, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Department of Pediatrics, Istanbul/TURKEY Nurcan Ucuncu Ergun, Postdoctorate Fellow of Pediatric Nutrition and Metabolism, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Department of Pediatrics, Istanbul/TURKEY Seyma Topuz, Nutritionist, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Department of Pediatric Nutrition and Metabolism, Istanbul/TURKEY Seda Yılmaz Semerci, Neonatalogist, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Division of Neonatology, Istanbul/TURKEY Nurettin Suner, Medical Doctor, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Division of General Medicine, Istanbul/TURKEY This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3682517 2 Ali Kocatas, Professor of General Surgery, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Department of General Surgery, Administrator/Director of Hospital, Istanbul/TURKEY Hasan Onal, Professor of Pediatrics, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Chief of Pediatric Nutrition and Metabolism Department, Istanbul/TURKEY Running title: Quercetin and Vitamin C Supplement Against COVID-19 *Corresponding author: Hasan Onal, MD Word Count: 1835 Number of Figures: 2 Number of Tables: 3 Turgut Özal Bulvarı No: 1, 34303 Ataşehir Küçükçekmece, İstanbul / TURKEY Tel: +90 532 509 29 88; Fax: 0 212 571 47 90 E-mail: hasanonal@hotmail.com ORCID ID: https://orcid.org/0000-0001-9676-7086 This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3682517 3 Summary Background While waiting for vaccine, hygiene measures, social distance and personal protective equipment are the only basic protection against Novel Coronavirus. However, these are not sufficient to protect healthcare workers.This study aimed to evaluate if quercetin and vitamin C could be protective against Novel Coronavirus. Methods In prophylaxis group supplementation containing 500mg of quercetin, 500mg of vitamin C and 50mg of bromelain (QCB) was initiated daily in 2 divided doses for 71 healthcare workers working in areas with high risk of COVID-19, whereas 42 were determined as control group without using supplements.A maximum period of follow-up was determined as 120 days.Termination of use of QCB earlier or having a Coronavirus infection was considered as final point.At the end rapid diagnostic test used to detect immunoglobulin positivity. Results A total of 113 persons included. No significant difference detected between groups in terms of other features.Mean age of..
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit